The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment.

Flint A, Kapitza C, Zdravkovic M

Diabetes, obesity & metabolism23 Apr 2013Cited by 36 (Europe PMC)

PMID23551925DOI10.1111/dom.12108PepBankPUB-23551925

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, mean postprandial hunger ratings were lower with liraglutide 1.8 mg than with placebo after 3 weeks.
In plain wordsIn adults with type 2 diabetes, people felt less hungry after meals on liraglutide than on placebo.
Peptide
Liraglutide
Outcome
DecreasePostprandial hunger ratings
Study
n = 18
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.8 mg once daily (weekly increments of 0.6 mg) · subcutaneous · 3 weeksAs given in this study (human).
Source sentences
Summary
After 3 weeks, mean postprandial and minimum hunger ratings were significantly lower with liraglutide 1.8 mg than placebo (p < 0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
The aim was to investigate effects of liraglutide on appetite and energy intake in a randomized, placebo-controlled, double-blind, crossover study.
Summary · context
Eighteen subjects with type 2 diabetes were assigned to treatment with once-daily subcutaneous liraglutide (increasing by weekly 0.6 mg increments) or placebo for 3 weeks.
Report a problemFND-2355192501
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, minimum hunger ratings were lower with liraglutide 1.8 mg than with placebo after 3 weeks.
In plain wordsIn adults with type 2 diabetes, the lowest hunger ratings were lower on liraglutide than on placebo.
Peptide
Liraglutide
Outcome
DecreaseMinimum hunger ratings
Study
n = 18
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.8 mg once daily (weekly increments of 0.6 mg) · subcutaneous · 3 weeksAs given in this study (human).
Source sentences
Summary
After 3 weeks, mean postprandial and minimum hunger ratings were significantly lower with liraglutide 1.8 mg than placebo (p < 0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
The aim was to investigate effects of liraglutide on appetite and energy intake in a randomized, placebo-controlled, double-blind, crossover study.
Summary · context
Eighteen subjects with type 2 diabetes were assigned to treatment with once-daily subcutaneous liraglutide (increasing by weekly 0.6 mg increments) or placebo for 3 weeks.
Report a problemFND-2355192502
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the mean overall appetite score was significantly higher with liraglutide than placebo, indicating reduced appetite.
In plain wordsIn adults with type 2 diabetes, the overall appetite score was higher with liraglutide than placebo, which means less appetite.
Peptide
Liraglutide
Outcome
IncreaseOverall appetite score
Study
n = 18
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.8 mg once daily (weekly increments of 0.6 mg) · subcutaneous · 3 weeksAs given in this study (human).
Source sentences
Summary
and the mean overall appetite score was significantly higher (p = 0.05), indicating reduced appetite.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim was to investigate effects of liraglutide on appetite and energy intake in a randomized, placebo-controlled, double-blind, crossover study.
Summary · context
Eighteen subjects with type 2 diabetes were assigned to treatment with once-daily subcutaneous liraglutide (increasing by weekly 0.6 mg increments) or placebo for 3 weeks.
Report a problemFND-2355192503
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, maximum fullness ratings were higher with liraglutide than with placebo.
In plain wordsIn adults with type 2 diabetes, people felt fuller on liraglutide than on placebo.
Peptide
Liraglutide
Outcome
IncreaseMaximum fullness ratings
Study
n = 18
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.8 mg once daily (weekly increments of 0.6 mg) · subcutaneous · 3 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide was associated with higher maximum fullness ratings (p = 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
The aim was to investigate effects of liraglutide on appetite and energy intake in a randomized, placebo-controlled, double-blind, crossover study.
Summary · context
Eighteen subjects with type 2 diabetes were assigned to treatment with once-daily subcutaneous liraglutide (increasing by weekly 0.6 mg increments) or placebo for 3 weeks.
Report a problemFND-2355192504
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, minimum ratings of prospective food consumption were lower with liraglutide than with placebo.
In plain wordsIn adults with type 2 diabetes, people expected to eat less on liraglutide than on placebo.
Peptide
Liraglutide
Outcome
DecreaseMinimum prospective food consumption ratings
Study
n = 18
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.8 mg once daily (weekly increments of 0.6 mg) · subcutaneous · 3 weeksAs given in this study (human).
Source sentences
Summary
and lower minimum ratings of prospective food consumption (p = 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
The aim was to investigate effects of liraglutide on appetite and energy intake in a randomized, placebo-controlled, double-blind, crossover study.
Summary · context
Eighteen subjects with type 2 diabetes were assigned to treatment with once-daily subcutaneous liraglutide (increasing by weekly 0.6 mg increments) or placebo for 3 weeks.
Report a problemFND-2355192505
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, mean estimated energy intake at lunch was 18% lower with liraglutide than with placebo.
In plain wordsIn adults with type 2 diabetes, people ate 18% less at lunch on liraglutide than on placebo.
Peptide
Liraglutide
Outcome
DecreaseAd libitum energy intake
Study
n = 18
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.8 mg once daily (weekly increments of 0.6 mg) · subcutaneous · 3 weeksAs given in this study (human).
Measurements
Estimated energy intake ratio
0.82 ratio
liraglutide/placebo
Source sentences
Summary
Mean estimated energy intake was 18% lower for liraglutide than placebo [estimated ratio 0.82 (95% CI 0.73;0.94); p = 0.004]
2 context sentences(design, population, supporting numbers)
Summary · context
The aim was to investigate effects of liraglutide on appetite and energy intake in a randomized, placebo-controlled, double-blind, crossover study.
Summary · context
Eighteen subjects with type 2 diabetes were assigned to treatment with once-daily subcutaneous liraglutide (increasing by weekly 0.6 mg increments) or placebo for 3 weeks.
Report a problemFND-2355192506
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide did not significantly change macronutrient distribution compared with placebo.
In plain wordsIn adults with type 2 diabetes, liraglutide did not change the mix of nutrients eaten compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeMacronutrient distribution
Study
n = 18
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.8 mg once daily (weekly increments of 0.6 mg) · subcutaneous · 3 weeksAs given in this study (human).
Source sentences
Summary
but no significant differences in macronutrient distribution were noted.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim was to investigate effects of liraglutide on appetite and energy intake in a randomized, placebo-controlled, double-blind, crossover study.
Summary · context
Eighteen subjects with type 2 diabetes were assigned to treatment with once-daily subcutaneous liraglutide (increasing by weekly 0.6 mg increments) or placebo for 3 weeks.
Report a problemFND-2355192507

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT01517555

Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 18Oct 2006 to May 2007

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 26 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.